Celldex Therapeutics, Inc. (CLDX) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $0.72, down from yesterday’s close by -6.48%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.Fundamental Analysis
Celldex Therapeutics, Inc. (CLDX) currently trades with a market capitalization of $100.16 Million. That value represents a market adjusting for revenues that have been growing by 84.52 % on a quarterly year/year basis as of the company’s last quarterly report.
You can get a sense of how sustainable that is by a levered free cash flow of -$101.72 Million over the past twelve months. Generally speaking, earnings are expected to hold steady in coming quarters. Analysts are forecasting earnings of -$0.2 on a per share basis this quarter. Perhaps, that suggests something about why 4.70% of the outstanding share supply is held by institutional investors.
As most professionals know, technical analysis can offer critical insights into what smart money and insiders think about a stock’s prospects going forward. Looking at the stock’s movement on the chart, Celldex Therapeutics, Inc. recorded a 52-week high of $3.27. It is now trading 2.55% off that level. The stock is trading $1.75 its 50-day moving average by 1.03%. The stock carved out a 52-week low down at $0.65.
In recent action, Celldex Therapeutics, Inc. (CLDX) has made a move of -67.86% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 12.84, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 7.52% with $138.90 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of CLDX.